Acute Heart Failure Management 2025: ED-to-RPM Protocol

Last updated: July 14, 2026

Key Takeaways

• Acute heart failure carries 20–25% 30-day readmission rates, so structured ED-to-RPM protocols help reduce CMS penalties and improve throughput.
• Immediate stabilization follows an ABCDE survey with prompt IV loop diuretics, vasodilators when appropriate, and rapid hemodynamic profiling to guide therapy.
• Correct hemodynamic profiling (warm-wet, cold-wet, etc.) within minutes directs first-line interventions and determines escalation to inotropes or mechanical support.
• Structured remote patient monitoring after discharge reduces HF hospitalizations and mortality, and AI-powered alert triage enables early intervention before readmission.
• Schedule a demo with Rhythm360 to implement a complete ED-to-RPM workflow that closes the post-discharge monitoring gap.

ABCDE Stabilization in the ED

Immediate stabilization follows a structured ABCDE survey. Initial steps include upright positioning, IV access, continuous cardiac monitoring, pulse oximetry, and supplemental oxygen titrated to SpO₂ ≥90%. The 2025 expert consensus recommends prompt initiation of definitive therapy upon ED presentation without waiting for a complete diagnostic workup.

The following numbered checklist summarizes the initial stabilization sequence:

1. Perform ABCDE survey and position the patient upright.
2. Establish IV access and attach continuous cardiac monitor and pulse oximeter.
3. Deliver supplemental oxygen at 4–6 L/min via face mask if SaO₂ <90%. Avoid routine oxygen in non-hypoxic patients because of vasoconstriction risk.
4. Initiate CPAP or BiPAP when respiratory distress persists (RR >25/min, SpO₂ <90%) despite conventional oxygen. Typical BiPAP settings include IPAP 6–12 cmH₂O and EPAP 4–8 cmH₂O.
5. Obtain 12-lead ECG, chest X-ray, troponin, and BNP/NT-proBNP simultaneously with treatment initiation.
6. Draw CBC, comprehensive metabolic panel, BUN/creatinine, LFTs, TSH, and urinalysis within the first hour.
7. Triage to the resuscitation bay if RR >25/min, SpO₂ <90% on supplemental oxygen, or SBP <90 mmHg.
8. Perform 2D echocardiography with Doppler within 48 hours to assess LVEF, wall motion, and valve function.

First-Line IV Diuretics and Vasodilators

IV loop diuretics form the pharmacologic cornerstone of AHF management. No 2026 JACC review exists in the evidence. 2024 JACC analyses and related sources discuss variable IV furosemide dosing, commonly 40–80 mg, for diuretic-naïve AHF patients based on congestion severity. Adjunctive vasodilators are appropriate when SBP exceeds 110 mmHg.

Dosing and response logic:

• Diuretic-naïve or low-dose maintenance: Furosemide 40–80 mg IV bolus, or bumetanide 0.5–1 mg IV one to three times daily.
• Established diuretic therapy: Administer 1–2.5× the usual oral dose intravenously.
• Response assessment at 2 hours: Target urine output ≥300 mL/2 h or urinary sodium ≥70 mmol/L. If not met, double the loop diuretic dose and consider adding acetazolamide or a thiazide.
• Refractory diuresis (>240 mg/day IV furosemide): Use sequential nephron blockade with metolazone 2.5–5 mg PO or chlorothiazide 500–1000 mg IV with close electrolyte monitoring.
• Vasodilators when SBP >110 mmHg: Start sodium nitroprusside at 0.3 µg/kg/min or nitroglycerin at 10–20 µg/min per institutional protocol.
• Hypotensive AHF (SBP <90 mmHg): Give a fluid challenge of 200–500 mL normal saline over 15–30 minutes if no overt fluid overload. If hypoperfusion persists, initiate norepinephrine and consider dobutamine.

Hemodynamic Profiles and Bedside Decisions

Correct hemodynamic profiling links directly to the treatment decisions outlined above. The choice of diuretics, vasodilators, inotropes, or fluid challenges depends on the patient’s profile at presentation. The warm-and-wet (wet-warm) profile, defined as adequate end-organ perfusion with elevated filling pressures, is the most common AHF presentation and accounts for approximately 70% of admissions for acute heart failure. Identifying the correct profile at the bedside within minutes directs the entire treatment strategy and determines which patients require escalation to inotropes or mechanical support.

See how Rhythm360 supports post-stabilization monitoring for every hemodynamic profile. Schedule a demo.

CHAMPIT Precipitants and Red-Flag Deterioration

The 2021 ESC Heart Failure Guidelines recognize life-threatening precipitants via the CHAMPIT framework: acute Coronary syndrome, Hypertension emergency, Arrhythmia, acute Mechanical causes, Pulmonary embolism, tamponade (cardiac Tamponade), and Infection. Each category requires urgent correction before standard HF management. Medication and dietary noncompliance frequently trigger decompensation, along with uncontrolled hypertension, atrial tachyarrhythmias, and infection. Uncontrolled hypertension occurs in approximately 50% of acute decompensated heart failure cases. Multiple precipitants often coexist in older adults with acute decompensated heart failure, so clinicians should systematically evaluate all contributors.

Red-flag criteria that require immediate escalation to inotropes or mechanical support include:

1. Altered mental status suggesting hypoperfusion
2. Narrow pulse pressure with cool, clammy skin or peripheral cyanosis
3. Urine output <30 mL/hr or rapid weight gain >2 lb/24 h
4. Flash pulmonary edema with pink frothy sputum or single-word dyspnea
5. Rising lactate despite vasopressors, cold mottled extremities, or falling MAP
6. In-hospital worsening heart failure (InH-WHF), which carries a two- to fourfold greater risk of all-cause death at 6 months post-discharge.

Restarting and Escalating GDMT Before Discharge

The 2024 ACC Expert Consensus defines hemodynamic stability for GDMT initiation as no IV vasodilators or escalating IV diuretics for 6 hours and no IV inotropes for 24 hours. All four foundational drug classes should start before discharge rather than waiting for outpatient follow-up.

Escalation thresholds and sequencing:

1. SGLT2 inhibitor first: Use dapagliflozin 10 mg or empagliflozin 10 mg daily after hemodynamic stability, with no persistent hypotension, no rapidly worsening renal function, and no active severe genitourinary infection. No titration is required.
2. ARNI (sacubitril/valsartan): Allow a 36-hour washout after the last ACE inhibitor dose. ARNI is preferred over ACEi because it provides at least 20% greater mortality reduction.
3. Beta-blocker: Continue stable chronic doses and hold if cardiogenic shock or IV inotropes are required. Initiate low-dose carvedilol, metoprolol succinate, or bisoprolol once the patient is euvolemic.
4. MRA: Start simultaneously with SGLT2i when SBP and renal function permit, and monitor potassium closely.
5. Post-discharge uptitration: Increase one medication at a time every 1–2 weeks. Creatinine rises up to 30% above baseline remain acceptable.
6. Inotrope escalation threshold: If SBP remains <90 mmHg after a 250 mL fluid challenge over 10 minutes, initiate dobutamine, milrinone, or dopamine. Norepinephrine is the preferred vasopressor if cardiogenic shock persists.

Transition-to-Remote-Monitoring Workflow

Discharge without structured remote monitoring leaves a critical surveillance gap during the highest-risk post-discharge window. The TIM-HF2 trial was among the first to show that remote patient management can reduce the proportion of days lost due to unplanned cardiovascular hospitalizations and all-cause death versus standard care. Building on that finding, a 2026 meta-analysis of 79 randomized trials involving 31,669 heart failure patients confirmed that remote monitoring reduced total HF hospitalizations (IRR 0.81), first HF hospitalizations (RR 0.82), and all-cause mortality (RR 0.90) compared with standard care, establishing the evidence base for routine RPM implementation.

A structured ED-to-RPM transition workflow includes the following steps:

1. Pre-discharge enrollment: Enroll the patient in an RPM program for heart failure and hypertension before leaving the hospital, and confirm device connectivity for scale, blood pressure cuff, and pulse oximeter.
2. Baseline thresholds set: Document individualized alert thresholds for weight gain (>2 lb/24 h or >5 lb/week), SBP, SpO₂, and heart rate based on the patient’s hemodynamic profile.
3. CIED data integration: For patients with implantable devices (pacemakers, ICDs, CRT-Ds, or CardioMEMS sensors), aggregate device transmissions alongside RPM data into a unified dashboard to detect rising filling pressures or new arrhythmias.
4. AI-powered alert triage: Clinically significant alerts, such as new-onset atrial fibrillation, weight gain trends, or abnormal pulmonary artery pressures, are prioritized and routed to the care team. This approach reduces alert fatigue and cuts cardiovascular hospitalization rates.
5. Follow-up within 7 days: Schedule a telehealth or in-person visit for GDMT uptitration review, electrolyte check, and renal function assessment.
6. Ongoing documentation: Automated CPT-compliant documentation supports billing for RPM services (for example, 99453, 99454, 99457) and reduces administrative burden on clinical staff.

Rhythm360 is a vendor-neutral, HIPAA-compliant platform that aggregates CIED data from all major device manufacturers, including Medtronic, Boston Scientific, Abbott, Biotronik, and others, alongside RPM physiological data into a single AI-powered dashboard. With greater than 99.9% data transmissibility achieved through redundant data feeds, computer vision, and AI-powered extrapolation, Rhythm360 enables practices to detect early decompensation signals and act before a readmission occurs.

Close the post-discharge monitoring gap. Schedule a demo with Rhythm360 today.

Frequently Asked Questions

How do I adjust IV loop diuretic dosing when urine output falls below target?

Clinicians should double the loop diuretic dose on the next administration when urine output falls below 300 mL over the first 2 hours or urinary sodium remains below 70 mmol/L after an initial IV loop diuretic dose. If the patient already receives high-dose furosemide exceeding 240 mg per day intravenously without adequate response, sequential nephron blockade becomes the next step. This strategy adds a thiazide-type agent, such as metolazone 2.5–5 mg orally or chlorothiazide 500–1000 mg intravenously, to block sodium reabsorption at a different nephron segment. Clinicians should monitor serum potassium, magnesium, sodium, and creatinine closely during combination diuretic therapy because electrolyte depletion can occur rapidly. Continuous urine output measurement via bladder catheter improves accuracy in the acute setting. If renal function worsens significantly, reassess volume status and consider whether cardiorenal syndrome limits diuretic responsiveness.

When should a patient with acute heart failure be hospitalized versus managed with RPM?

New-onset acute heart failure generally requires inpatient management at initial presentation, with echocardiography and evaluation of the underlying etiology. Hospitalization is indicated for any patient with persistent hemodynamic instability, ongoing severe respiratory distress, cardiogenic shock, need for intubation or ventilation, or norepinephrine requirements above 0.2 mcg/kg/min. Patients with known chronic heart failure who present with mild-to-moderate decompensation, stable hemodynamics, SpO₂ that responds to supplemental oxygen, and no signs of end-organ hypoperfusion may qualify for intensive outpatient management paired with immediate RPM enrollment, provided close follow-up within 24–72 hours is confirmed. RPM then becomes the primary surveillance tool after hospital discharge, enabling detection of weight gain trends, rising filling pressures, or new arrhythmias before they escalate to a readmission. Rhythm360 supports this transition by aggregating physiological data and CIED transmissions into a single dashboard with AI-driven alert prioritization, allowing the care team to intervene early in the post-discharge period.

How does Rhythm360 integrate remote physiological monitoring data with existing EHR workflows?

Rhythm360 offers bi-directional EHR integration with major platforms including Epic, Cerner, Athenahealth, eClinicalWorks, and Greenway Health via HL7, with onboarding typically completed within a few days to a few weeks. On the device side, the platform ingests data from all major CIED manufacturers through APIs, HL7, XML, and PDF parsing via computer vision, and normalizes disparate data streams into a single source of truth. For heart failure and hypertension RPM, Rhythm360 supports turnkey service line launch with automated billing documentation for relevant CPT codes, which reduces the administrative burden on clinical staff. Clinicians access a unified dashboard that displays CIED transmissions, RPM physiological readings, and AI-prioritized alerts in one view, eliminating the need to log into multiple OEM portals. A secure, HIPAA-compliant mobile application allows clinicians to review transmissions, sign reports, and coordinate care from anywhere. Practices using Rhythm360 have reported up to an 80% reduction in critical alert response times and significant improvements in revenue capture through more complete CPT code billing.

Conclusion and Next Steps

Effective acute heart failure management in 2025 spans the full continuum from ABCDE stabilization and hemodynamic profiling in the ED through first-line diuretic and vasodilator therapy, precipitant identification using the CHAMPIT framework, and in-hospital GDMT initiation, then continues into a structured post-discharge RPM transition. Protocols that stop at hospital discharge leave patients in the highest-risk window without surveillance, exposing practices to readmission penalties and patients to preventable harm. The meta-analysis evidence cited earlier, spanning 79 randomized trials, confirms that remote monitoring reduces HF hospitalizations and all-cause mortality when implemented with proactive, data-driven workflows.

Rhythm360 provides the vendor-neutral, AI-powered infrastructure that makes this transition seamless by aggregating CIED and RPM data from every major manufacturer into one dashboard, automating documentation, and enabling early intervention before decompensation becomes a readmission.

Schedule a demo to see how Rhythm360 completes your acute heart failure protocol from stabilization through post-discharge monitoring.